Johnson & Johnson JNJ Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales to customers (Note 9) by Business | ||||||
| Innovative Medicine | $61.95B+2.6% | $60.4B+2.4% | $58.97B+1.7% | $57.99B+1.2% | $57.28B+0.5% | |
| MEDTECH | $34.41B+1.8% | $33.79B+1.8% | $33.18B+1.7% | $32.64B+1.8% | $32.06B+0.6% | |
| Other (income) expense, net by Business | ||||||
| Innovative Medicine | -$559M+21.6% | -$713M+1.1% | -$721M-41.9% | -$508M-5.6% | -$481M-12.9% | |
| MEDTECH | $1.07B+14.5% | $938M+334% | $216M+6.4% | $203M-16.8% | $244M-5.1% | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest by Business | ||||||
| Innovative Medicine | $22.37B+0.5% | $22.27B+4.9% | $21.22B+10.2% | $19.25B+0.5% | $19.16B+1.3% | |
| MEDTECH | $3.93B-4.4% | $4.11B+3.2% | $3.98B+6.1% | $3.76B+3.2% | $3.64B-2.6% | |
| Total Assets by Business | ||||||
| General Corporate | $134.32B-9.0% | $147.55B-2.7% | $151.59B— | —— | —— | |
| Innovative Medicine | $306.08B+6.8% | $286.69B+7.9% | $265.71B— | —— | —— | |
| MEDTECH | $345.91B+0.3% | $344.84B+0.6% | $342.68B— | —— | —— | |
| Cost of products sold by Business | ||||||
| Innovative Medicine | $16.02B+2.4% | $15.65B+3.0% | $15.18B+0.8% | $15.06B+2.6% | $14.69B+4.6% | |
| MEDTECH | $14.92B+2.6% | $14.55B+2.7% | $14.17B+1.7% | $13.94B+2.9% | $13.55B+1.5% | |
| Depreciation and Amortization by Business | ||||||
| General Corporate | $254M+5.4% | $241M+3.4% | $233M-13.7% | $270M-19.6% | $336M-1.8% | |
| Innovative Medicine | $3.92B+4.0% | $3.77B+1.3% | $3.72B-2.6% | $3.82B+5.3% | $3.63B-3.4% | |
| MEDTECH | $3.56B+1.9% | $3.49B+1.7% | $3.43B+2.0% | $3.36B+1.1% | $3.33B+2.8% | |
| Selling, marketing and administrative expenses by Business | ||||||
| Innovative Medicine | $12.03B+5.8% | $11.38B+1.3% | $11.23B+3.5% | $10.85B+1.2% | $10.73B-1.6% | |
| MEDTECH | $11.6B+2.2% | $11.35B+1.8% | $11.16B+0.7% | $11.08B+1.8% | $10.89B+0.7% | |
| Research and development expense by Business | ||||||
| Innovative Medicine | $12.09B+2.2% | $11.83B-1.9% | $12.06B-9.5% | $13.33B+1.1% | $13.18B-2.6% | |
| MEDTECH | $2.88B+1.3% | $2.84B-22.3% | $3.65B-0.3% | $3.66B-1.9% | $3.73B+0.8% | |
| Additions to Property, Plant & Equipment by Business | ||||||
| General Corporate | $248M-2.7% | $255M+19.2% | $214M+9.7% | $195M-14.5% | $228M-15.9% | |
| Innovative Medicine | $2.31B+11.2% | $2.08B+9.0% | $1.91B+3.3% | $1.84B+5.1% | $1.75B+2.6% | |
| MEDTECH | $2.53B+1.2% | $2.5B+0.5% | $2.49B+2.0% | $2.44B+0.4% | $2.43B-0.5% | |
| Goodwill, Written off Related to Sale of Business Unit by Business | ||||||
| Innovative Medicine | $0— | $0— | $0— | $0— | $0— | |
| Percent Change (as a percent) by Business | ||||||
| Innovative Medicine | 78.2%+9.7pp | 68.5%+10.1pp | 58.4%+2.6pp | 55.8%+8.3pp | 47.5%+70.6pp | |
| Goodwill (Note 3) by Business | ||||||
| Innovative Medicine | $58.37B+7.2% | $54.47B+8.5% | $50.19B+6.7% | $47.04B+8.2% | $43.48B+0.8% | |
| MEDTECH | $135.12B+0.1% | $134.94B+0.2% | $134.64B+0.1% | $134.55B+0.2% | $134.24B+5.9% | |
| Currency translation/Other by Business | ||||||
| Innovative Medicine | $445M-45.4% | $815M+156% | $318M-47.4% | $605M+12,000% | $5M+101% | |
| MEDTECH | $196M-41.8% | $337M+157% | $131M-50.2% | $263M+1,923% | $13M+108% | |
| Goodwill, related to acquisitions by Business | ||||||
| Innovative Medicine | $3.52B0.0% | $3.52B+21.5% | $2.9B-1.9% | $2.95B+744% | $350M-45.3% | |
| MEDTECH | $0— | $0-100% | $2M-97.3% | $75M-99.0% | $7.57B0.0% | |
| Sales to customers (Note 9) by Product | ||||||
| ADVANCED | $4.63B+1.1% | $4.58B+0.5% | $4.55B+1.2% | $4.5B+0.5% | $4.47B-0.3% | |
| CAPLYTA | $970M+38.6% | $700M+55.2% | $451M+114% | $211M— | $0— | |
| CARVYKTI | $2.12B+12.1% | $1.89B+13.3% | $1.67B+16.7% | $1.43B+21.5% | $1.18B+22.0% | |
| CONCERTA/Methylphenidate | $572M-2.1% | $584M-4.4% | $611M-0.3% | $613M+0.2% | $612M-4.5% | |
| CONTACT LENSES / OTHER | $3.96B+1.3% | $3.91B+1.8% | $3.84B+1.3% | $3.79B+1.3% | $3.74B+0.2% | |
| DARZALEX | $15.08B+5.1% | $14.35B+6.1% | $13.53B+5.1% | $12.88B+5.4% | $12.22B+4.7% | |
| EDURANT/rilpivirine | $1.54B+3.4% | $1.49B+4.3% | $1.43B+4.0% | $1.37B+4.8% | $1.31B+2.8% | |
| ERLEADA | $3.75B+5.0% | $3.57B+5.1% | $3.4B+4.5% | $3.25B+5.6% | $3.08B+2.7% | |
| GENERAL | $5.63B+1.2% | $5.56B+2.0% | $5.45B+1.0% | $5.4B+0.8% | $5.35B-0.1% | |
| HIPS | $1.7B+1.6% | $1.67B+1.3% | $1.65B+1.5% | $1.63B+0.2% | $1.63B-0.8% | |
| IMBRUVICA | $2.77B-1.7% | $2.82B-1.6% | $2.87B-2.0% | $2.93B-1.2% | $2.96B-2.5% | |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | $3.95B+3.5% | $3.81B-2.0% | $3.89B-3.0% | $4.01B-1.5% | $4.07B-3.6% | |
| KNEES | $1.62B+2.0% | $1.59B+2.2% | $1.55B+1.6% | $1.53B-0.3% | $1.53B-0.8% | |
| OTHER IMMUNOLOGY | $106M+73.8% | $61M+190% | $21M+110% | $10M+150% | $4M+33.3% | |
| OTHER INFECTIOUS DISEASES | $171M-2.3% | $175M-2.8% | $180M-4.8% | $189M-49.6% | $375M-9.0% | |
| OTHER NEUROSCIENCE | $1.03B-1.4% | $1.05B-0.9% | $1.06B-2.3% | $1.08B-2.2% | $1.11B-5.8% | |
| Other Oncology | $479M-4.4% | $501M+5.3% | $476M+1.7% | $468M+2.2% | $458M+44.5% | |
| Other | $3.72B+1.6% | $3.66B-0.9% | $3.69B-0.8% | $3.72B+0.1% | $3.72B+213% | |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | $1.62B+2.5% | $1.58B-1.5% | $1.6B-3.1% | $1.66B-2.5% | $1.7B-0.9% | |
| Remicade | $1.72B-2.5% | $1.77B+0.6% | $1.76B+3.4% | $1.7B+3.8% | $1.64B+2.1% | |
| RYBREVANT + LAZCLUZE | $850M+15.8% | $734M+14.7% | $640M+20.5% | $531M+26.1% | $421M+28.7% | |
| SIMPONI / SIMPONI ARIA | $2.66B-0.4% | $2.67B+1.9% | $2.62B+7.0% | $2.45B+6.7% | $2.3B+4.8% | |
| SPRAVATO | $1.84B+8.7% | $1.7B+13.8% | $1.49B+13.3% | $1.32B+12.2% | $1.17B+8.8% | |
| STELARA | $5.11B-15.9% | $6.08B-15.5% | $7.2B-13.3% | $8.3B-12.9% | $9.54B-8.0% | |
| SURGICAL | $1.59B+2.2% | $1.56B+3.0% | $1.51B+3.4% | $1.46B+2.5% | $1.43B+0.9% | |
| TALVEY | $529M+14.3% | $463M+16.0% | $399M+13.4% | $352M+11.7% | $315M+9.8% | |
| Tecvayli | $721M+7.6% | $670M+4.7% | $640M+7.0% | $598M+5.5% | $567M+3.3% | |
| TRAUMA | $3.21B+1.9% | $3.15B+1.6% | $3.1B+1.0% | $3.07B+0.3% | $3.06B+0.2% | |
| Tremfya | $5.81B+12.6% | $5.16B+14.2% | $4.52B+10.2% | $4.1B+7.3% | $3.82B+4.0% | |
| UPTRAVI | $1.93B+1.7% | $1.9B+1.4% | $1.88B+1.4% | $1.85B+2.8% | $1.8B-0.9% | |
| XARELTO | $2.59B-1.8% | $2.63B+0.4% | $2.62B+1.7% | $2.58B+1.3% | $2.55B+7.2% | |
| Percent Change (as a percent) by Product | ||||||
| ADVANCED | 11.7%+5.8pp | 5.9%— | —— | —— | —— | |
| CAPLYTA | 0%— | 0%— | 0%— | 0%— | 0%— | |
| CONCERTA/Methylphenidate | -11.9%+8.3pp | -20.2%— | —— | —— | —— | |
| CONTACT LENSES / OTHER | 16.8%+4.5pp | 12.3%-0.7pp | 13%+1.0pp | 12%+7.3pp | 4.7%+5.6pp | |
| DARZALEX | 68.5%+2.2pp | 66.3%+0.8pp | 65.5%+1.0pp | 64.5%+4.6pp | 59.9%+1.4pp | |
| EDURANT/rilpivirine | 52.9%+3.4pp | 49.5%— | —— | —— | —— | |
| ERLEADA | 66.1%+11.2pp | 54.9%— | —— | —— | —— | |
| GENERAL | 13.6%+5.4pp | 8.2%+1.7pp | 6.5%+3.1pp | 3.4%+5.2pp | -1.8%-1.5pp | |
| HIPS | 14.7%+9.6pp | 5.1%— | —— | —— | —— | |
| KNEES | 15.8%+10.9pp | 4.9%— | —— | —— | —— | |
| Other Oncology | 15.3%-32.3pp | 47.6%+101pp | -53.7%-15.1pp | -38.6%-72.5pp | 33.9%-58.5pp | |
| SPRAVATO | 165.6%+4.5pp | 161.1%— | —— | —— | —— | |
| STELARA | -145.5%-26.0pp | -119.5%+1.6pp | -121.1%-34.7pp | -86.4%-45.8pp | -40.6%-34.0pp | |
| SURGICAL | 35.3%+6.0pp | 29.3%-2.1pp | 31.4%+13.6pp | 17.8%+10.4pp | 7.4%+3.4pp | |
| TALVEY | 198.5%+28.3pp | 170.2%— | —— | —— | —— | |
| TRAUMA | 14.5%+7.1pp | 7.4%+0.9pp | 6.5%+1.6pp | 4.9%-1.6pp | 6.5%-0.1pp | |
| Tremfya | 150.1%+50.1pp | 100%— | —— | —— | —— | |
| UPTRAVI | 24.8%+10.7pp | 14.1%— | —— | —— | —— | |
| Sales to customers (Note 9) by Geography | ||||||
| Asia-Pacific, Africa | $14.31B+2.0% | $14.03B+1.7% | $13.79B+1.0% | $13.65B+1.1% | $13.5B-0.7% | |
| Europe | $22.27B+3.4% | $21.54B+3.2% | $20.86B+2.6% | $20.33B+0.9% | $20.16B-0.3% | |
| United States | $54.78B+1.9% | $53.75B+1.9% | $52.76B+1.5% | $51.96B+1.9% | $50.99B+1.4% | |
| Western Hemisphere, excluding U.S. | $5B+2.6% | $4.88B+2.9% | $4.74B+1.2% | $4.68B-0.1% | $4.69B-0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Johnson & Johnson break its business down?
- Johnson & Johnson (JNJ) reports sales to customers (note 9) by business across 2 parts — Innovative Medicine and MEDTECH. Each is extracted from the segment footnotes and tracked over time.
- Where does Johnson & Johnson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Johnson & Johnson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
